These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. The serum CA-125 concentration data assists in evaluating CT imaging information when used to differentiate borderline ovarian tumor from malignant epithelial ovarian tumors. Shin JE; Choi HJ; Kim MH; Cho KS Korean J Radiol; 2011; 12(4):456-62. PubMed ID: 21852906 [TBL] [Abstract][Full Text] [Related]
47. Comparison of clinical behavior between mucinous ovarian carcinoma with infiltrative and expansile invasion and high-grade serous ovarian carcinoma: a retrospective analysis. Hada T; Miyamoto M; Ishibashi H; Matsuura H; Kakimoto S; Iwahashi H; Tsuda H; Takano M Diagn Pathol; 2022 Jan; 17(1):12. PubMed ID: 35057833 [TBL] [Abstract][Full Text] [Related]
48. The role of CnTI-SonoVue in the diagnosis of ovarian masses with papillary projections: a preliminary study. Testa AC; Timmerman D; Exacoustos C; Fruscella E; Van Holsbeke C; Bokor D; Arduini D; Scambia G; Ferrandina G Ultrasound Obstet Gynecol; 2007 May; 29(5):512-6. PubMed ID: 17444549 [TBL] [Abstract][Full Text] [Related]
49. Unilocular adnexal cysts with papillary projections but no other solid components: is there a diagnostic method that can classify them reliably as benign or malignant before surgery? Valentin L; Ameye L; Savelli L; Fruscio R; Leone FP; Czekierdowski A; Lissoni AA; Fischerova D; Guerriero S; Van Holsbeke C; Van Huffel S; Timmerman D Ultrasound Obstet Gynecol; 2013 May; 41(5):570-81. PubMed ID: 22915541 [TBL] [Abstract][Full Text] [Related]
50. Risk of specific types of ovarian cancer after borderline ovarian tumors in Denmark: A nationwide study. Hannibal CG; Frederiksen K; Vang R; Kurman RJ; Kjaer SK Int J Cancer; 2020 Aug; 147(4):990-995. PubMed ID: 31930502 [TBL] [Abstract][Full Text] [Related]
51. Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network. Gasimli K; Braicu EI; Nassir M; Richter R; Babayeva A; Chekerov R; Darb-Esfahani S; Sehouli J; Muallem MZ Ann Surg Oncol; 2016 Apr; 23(4):1279-86. PubMed ID: 26832880 [TBL] [Abstract][Full Text] [Related]
52. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis. Dehari R; Kurman RJ; Logani S; Shih IeM Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266 [TBL] [Abstract][Full Text] [Related]
53. Testing for Sadlecki P; Grzanka D; Grabiec M Dis Markers; 2018; 2018():1497879. PubMed ID: 29682098 [TBL] [Abstract][Full Text] [Related]
54. Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma. Chui MH; Momeni Boroujeni A; Mandelker D; Ladanyi M; Soslow RA Mod Pathol; 2021 Feb; 34(2):490-501. PubMed ID: 32801341 [TBL] [Abstract][Full Text] [Related]
55. Imaging in gynecological disease (9): clinical and ultrasound characteristics of tubal cancer. Ludovisi M; De Blasis I; Virgilio B; Fischerova D; Franchi D; Pascual MA; Savelli L; Epstein E; Van Holsbeke C; Guerriero S; Czekierdowski A; Zannoni G; Scambia G; Jurkovic D; Rossi A; Timmerman D; Valentin L; Testa AC Ultrasound Obstet Gynecol; 2014 Mar; 43(3):328-35. PubMed ID: 23893713 [TBL] [Abstract][Full Text] [Related]
56. Ovarian cancer arising in endometrioid cysts: ultrasound findings. Testa AC; Timmerman D; Van Holsbeke C; Zannoni GF; Fransis S; Moerman P; Vellone V; Mascilini F; Licameli A; Ludovisi M; Di Legge A; Scambia G; Ferrandina G Ultrasound Obstet Gynecol; 2011 Jul; 38(1):99-106. PubMed ID: 21351179 [TBL] [Abstract][Full Text] [Related]
57. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis. Sherman ME; Mink PJ; Curtis R; Cote TR; Brooks S; Hartge P; Devesa S Cancer; 2004 Mar; 100(5):1045-52. PubMed ID: 14983501 [TBL] [Abstract][Full Text] [Related]
58. Evaluation of MTAP immunohistochemistry loss of expression in ovarian serous borderline tumors as a potential marker for prognosis and progression. Nilforoushan N; Moatamed NA Ann Diagn Pathol; 2020 Oct; 48():151582. PubMed ID: 32866902 [TBL] [Abstract][Full Text] [Related]
59. Ovarian serous tumors of low malignant potential with nodal low-grade serous carcinoma. Djordjevic B; Malpica A Am J Surg Pathol; 2012 Jul; 36(7):955-63. PubMed ID: 22613998 [TBL] [Abstract][Full Text] [Related]
60. Expression and prognostic significance of epithelial-mesenchymal transition-related markers and phenotype in serous ovarian cancer. Song IH; Kim KR; Lim S; Kim SH; Sung CO Pathol Res Pract; 2018 Oct; 214(10):1564-1571. PubMed ID: 30082157 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]